VELURI

 PID No.
 : MED111034728
 Register On
 : 26/03/2022 10:15 AM

 SID No.
 : 422024590
 Collection On
 : 26/03/2022 12:03 PM

 Age / Sex
 : 49 Year(s) / Male
 Report On
 : 27/03/2022 4:19 PM

 Type
 : OP
 Printed On
 : 29/03/2022 4:33 PM

Ref. Dr : MediWheel

<u>Investigation</u>	Observed Value	<u>Unit</u>	Biological Reference Interval
HAEMATOLOGY			
Complete Blood Count With - ESR			
Haemoglobin (EDTA Blood/Spectrophotometry)	13.1	g/dL	13.5 - 18.0
Packed Cell Volume(PCV)/Haematocrit (EDTA Blood/Derived from Impedance)	40.8	%	42 - 52
RBC Count (EDTA Blood/Impedance Variation)	4.44	mill/cu.mm	4.7 - 6.0
Mean Corpuscular Volume(MCV) (EDTA Blood/Derived from Impedance)	92.0	fL	78 - 100
Mean Corpuscular Haemoglobin(MCH) (EDTA Blood/Derived from Impedance)	29.5	pg	27 - 32
Mean Corpuscular Haemoglobin concentration(MCHC) (EDTA Blood/Derived from Impedance)	32.1	g/dL	32 - 36
RDW-CV (EDTA Blood/Derived from Impedance)	17.1	%	11.5 - 16.0
RDW-SD (EDTA Blood/Derived from Impedance)	55.06	fL	39 - 46
Total Leukocyte Count (TC) (EDTA Blood/Impedance Variation)	6700	cells/cu.mm	4000 - 11000
Neutrophils (EDTA Blood/Impedance Variation & Flow Cytometry)	61.3	%	40 - 75
Lymphocytes (EDTA Blood/Impedance Variation & Flow Cytometry)	22.8	%	20 - 45





VELURI

 PID No.
 : MED111034728
 Register On
 : 26/03/2022 10:15 AM

 SID No.
 : 422024590
 Collection On
 : 26/03/2022 12:03 PM

 Age / Sex
 : 49 Year(s) / Male
 Report On
 : 27/03/2022 4:19 PM

 Type
 : OP
 Printed On
 : 29/03/2022 4:33 PM

Ref. Dr : MediWheel

Investigation	Observed <u>Value</u>	<u>Unit</u>	<u>Biological</u> <u>Reference Interval</u>
Eosinophils (EDTA Blood/Impedance Variation & Flow Cytometry)	3.4	%	01 - 06
Monocytes (EDTA Blood/Impedance Variation & Flow Cytometry)	11.9	%	01 - 10
Basophils (Blood/Impedance Variation & Flow Cytometry)	0.6	%	00 - 02
Absolute Neutrophil count (EDTA Blood/Impedance Variation & Flow Cytometry)	4.11	10^3 / μl	1.5 - 6.6
Absolute Lymphocyte Count (EDTA Blood/Impedance Variation & Flow Cytometry)	1.53	10^3 / μl	1.5 - 3.5
Absolute Eosinophil Count (AEC) (EDTA Blood/Impedance Variation & Flow Cytometry)	0.23	10^3 / μ1	0.04 - 0.44
Absolute Monocyte Count (EDTA Blood/Impedance Variation & Flow Cytometry)	0.80	10^3 / μl	< 1.0
Absolute Basophil count (EDTA Blood/Impedance Variation & Flow Cytometry)	0.04	10^3 / μ1	< 0.2
Platelet Count (EDTA Blood/Impedance Variation)	282	10^3 / μl	150 - 450
MPV (EDTA Blood/Derived from Impedance)	8.3	fL	7.9 - 13.7
PCT (EDTA Blood/Automated Blood cell Counter)	0.23	%	0.18 - 0.28
ESR (Erythrocyte Sedimentation Rate) (Citrated Blood/Modified Westergren)	5	mm/hr	< 15





VELURI

 PID No.
 : MED111034728
 Register On
 : 26/03/2022 10:15 AM

 SID No.
 : 422024590
 Collection On
 : 26/03/2022 12:03 PM

 Age / Sex
 : 49 Year(s) / Male
 Report On
 : 27/03/2022 4:19 PM

 Type
 : OP
 Printed On
 : 29/03/2022 4:33 PM

Ref. Dr : MediWheel

<u>Investigation</u>	Observed Value	<u>Unit</u>	<u>Biological</u> <u>Reference Interval</u>
BIOCHEMISTRY			
Liver Function Test			
Bilirubin(Total) (Serum/Diazotized Sulfanilic Acid)	0.5	mg/dL	0.1 - 1.2
Bilirubin(Direct) (Serum/Diazotized Sulfanilic Acid)	0.2	mg/dL	0.0 - 0.3
Bilirubin(Indirect) (Serum/Derived)	0.3	mg/dL	0.1 - 1.0
Total Protein (Serum/Biuret)	8.0	gm/dL	6.0 - 8.0
Albumin (Serum/Bromocresol green)	4.6	gm/dL	3.5 - 5.2
Globulin (Serum/Derived)	3.4	gm/dL	2.3 - 3.6
A : G Ratio (Serum/Derived)	1.4		1.1 - 2.2
SGOT/AST (Aspartate Aminotransferase) (Serum/IFCC Kinetic)	15	U/L	5 - 40
SGPT/ALT (Alanine Aminotransferase) (Serum/IFCC / Kinetic)	16	U/L	5 - 41
Alkaline Phosphatase (SAP) (Serum/IFCC Kinetic)	111	U/L	53 - 128
GGT(Gamma Glutamyl Transpeptidase) (Serum/SZASZ standarised IFCC)	17	U/L	< 55



VERIFIED BY



VELURI

 PID No.
 : MED111034728
 Register On
 : 26/03/2022 10:15 AM

 SID No.
 : 422024590
 Collection On
 : 26/03/2022 12:03 PM

 Age / Sex
 : 49 Year(s) / Male
 Report On
 : 27/03/2022 4:19 PM

 Type
 : OP
 Printed On
 : 29/03/2022 4:33 PM

Ref. Dr : MediWheel

Investigation	Observed Value	<u>Unit</u>	<u>Biological</u> <u>Reference Interval</u>
<u>Lipid Profile</u>			
Cholesterol Total (Serum/Cholesterol oxidase/Peroxidase)	133	mg/dL	Optimal: < 200 Borderline: 200 - 239 High Risk: >= 240
Triglycerides (Serum/Glycerol phosphate oxidase / peroxidase)	111	mg/dL	Optimal: < 150 Borderline: 150 - 199 High: 200 - 499 Very High: >= 500

INTERPRETATION: The reference ranges are based on fasting condition. Triglyceride levels change drastically in response to food, increasing as much as 5 to 10 times the fasting levels, just a few hours after eating. Fasting triglyceride levels show considerable diurnal variation too. There is evidence recommending triglycerides estimation in non-fasting condition for evaluating the risk of heart disease and screening for metabolic syndrome, as non-fasting sample is more representative of the õusualö"circulating level of triglycerides during most part of the day.

HDL Cholesterol (Serum/Immunoinhibition)	30	mg/dL	Optimal(Negative Risk Factor): >= 60 Borderline: 40 - 59 High Risk: < 40
LDL Cholesterol (Serum/Calculated)	80.8	mg/dL	Optimal: < 100 Above Optimal: 100 - 129 Borderline: 130 - 159 High: 160 - 189 Very High: >= 190
VLDL Cholesterol (Serum/Calculated)	22.2	mg/dL	< 30
Non HDL Cholesterol (Serum/Calculated)	103.0	mg/dL	Optimal: < 130 Above Optimal: 130 - 159 Borderline High: 160 - 189 High: 190 - 219 Very High: >= 220



VERIFIED BY



VELURI

 PID No.
 : MED111034728
 Register On
 : 26/03/2022 10:15 AM

 SID No.
 : 422024590
 Collection On
 : 26/03/2022 12:03 PM

 Age / Sex
 : 49 Year(s) / Male
 Report On
 : 27/03/2022 4:19 PM

 Type
 : OP
 Printed On
 : 29/03/2022 4:33 PM

Ref. Dr : MediWheel

InvestigationObservedUnitBiologicalValueReference Interval

INTERPRETATION: 1. Non-HDL Cholesterol is now proven to be a better cardiovascular risk marker than LDL Cholesterol. 2. It is the sum of all potentially atherogenic proteins including LDL, IDL, VLDL and chylomicrons and it is the "new bad cholesterol" and is a co-primary target for cholesterol lowering therapy.

Total Cholesterol/HDL Cholesterol Ratio 4.4

(Serum/*Calculated*)

Low Risk: 3.4 - 4.4

Average Risk: 4.5 - 7.1

Moderate Risk: 7.2 - 11.0

Ioderate Risk: 7.2 - 11.0 High Risk: > 11.0

Optimal: < 3.3

Triglyceride/HDL Cholesterol Ratio 3.7 Optimal: < 2.5

(TG/HDL) Mild to moderate risk: 2.5 - 5.0

(Serum/Calculated) High Risk: > 5.0

LDL/HDL Cholesterol Ratio 2.7 Optimal: 0.5 - 3.0

(Serum/Calculated)
Borderline: 3.1 - 6.0
High Risk: > 6.0



VERIFIED BY



VELURI

 PID No.
 : MED111034728
 Register On
 : 26/03/2022 10:15 AM

 SID No.
 : 422024590
 Collection On
 : 26/03/2022 12:03 PM

 Age / Sex
 : 49 Year(s) / Male
 Report On
 : 27/03/2022 4:19 PM

 Type
 : OP
 Printed On
 : 29/03/2022 4:33 PM

Ref. Dr : MediWheel

Investigation	Observed <u>Value</u>	<u>Unit</u>	<u>Biological</u> <u>Reference Interval</u>
Glycosylated Haemoglobin (HbA1c)			
HbA1C (Whole Blood/ <i>HPLC</i>)	7.7	%	Normal: 4.5 - 5.6 Prediabetes: 5.7 - 6.4 Diabetic: >= 6.5

INTERPRETATION: If Diabetes - Good control: 6.1 - 7.0 %, Fair control: 7.1 - 8.0 %, Poor control >= 8.1 %

Estimated Average Glucose 174.29 mg/dL

(Whole Blood)

INTERPRETATION: Comments

HbA1c provides an index of Average Blood Glucose levels over the past 8 - 12 weeks and is a much better indicator of long term glycemic control as compared to blood and urinary glucose determinations.

Conditions that prolong RBC life span like Iron deficiency anemia, Vitamin B12 & Folate deficiency,

hypertriglyceridemia, hyperbilirubinemia, Drugs, Alcohol, Lead Poisoning, Asplenia can give falsely elevated HbAlC values.

Conditions that shorten RBC survival like acute or chronic blood loss, hemolytic anemia, Hemoglobinopathies, Splenomegaly, Vitamin E ingestion, Pregnancy, End stage Renal disease can cause falsely low HbA1c.



VERIFIED BY



VELURI

 PID No.
 : MED111034728
 Register On
 : 26/03/2022 10:15 AM

 SID No.
 : 422024590
 Collection On
 : 26/03/2022 12:03 PM

 Age / Sex
 : 49 Year(s) / Male
 Report On
 : 27/03/2022 4:19 PM

Type : OP Printed On : 29/03/2022 4:33 PM

Ref. Dr : MediWheel

InvestigationObservedUnitBiologicalValueReference Interval

IMMUNOASSAY

THYROID PROFILE / TFT

T3 (Triiodothyronine) - Total 1.28 ng/mL 0.7 - 2.04

(Serum/CMIA)

INTERPRETATION:

Comment:

Total T3 variation can be seen in other condition like pregnancy, drugs, nephrosis etc. In such cases, Free T3 is recommended as it is

Metabolically active.

T4 (Thyroxine) - Total 9.04 μg/dL 4.2 - 12.0

(Serum/CMIA)

INTERPRETATION:

Comment:

Total T4 variation can be seen in other condition like pregnancy, drugs, nephrosis etc. In such cases, Free T4 is recommended as it is Metabolically active.

TSH (Thyroid Stimulating Hormone) 3.44 µIU/mL 0.35 - 5.50

(Serum/Chemiluminescent Microparticle

Immunoassay(CMIA))

INTERPRETATION:

Reference range for cord blood - upto 20

1 st trimester: 0.1-2.5 2 nd trimester 0.2-3.0 3 rd trimester : 0.3-3.0

(Indian Thyroid Society Guidelines)

Comment:

1.TSH reference range during pregnancy depends on Iodine intake, TPO status, Serum HCG concentration, race, Ethnicity and BMI.

2.TSH Levels are subject to circadian variation, reaching peak levels between 2-4am and at a minimum between 6-10PM. The variation can be of the order of 50%, hence time of the day has influence on the measured serum TSH concentrations.

3. Values & amplt 0.03 µIU/mL need to be clinically correlated due to presence of rare TSH variant in some individuals.



VELURI

 PID No.
 : MED111034728
 Register On
 : 26/03/2022 10:15 AM

 SID No.
 : 422024590
 Collection On
 : 26/03/2022 12:03 PM

 Age / Sex
 : 49 Year(s) / Male
 Report On
 : 27/03/2022 4:19 PM

 Type
 : OP
 Printed On
 : 29/03/2022 4:33 PM

Ref. Dr : MediWheel

InvestigationObserved
ValueUnit
Reference Interval

CLINICAL PATHOLOGY

PHYSICAL EXAMINATION

Colour Pale Yellow

(Urine)

Appearance Clear Clear

(Urine)

Volume 20 mL

(Urine)

CHEMICAL EXAMINATION(Automated-

<u>Urineanalyser)</u>

pH 6.0 4.5 - 8.0

(Urine/AUTOMATED URINANALYSER)

Specific Gravity 1.025 1.002 - 1.035

(Urine)

Ketones Negative Negative

(Urine)

Urobilinogen 0.2 0.2 - 1.0

(Urine/AUTOMATED URINANALYSER)

Blood Negative Negative

(Urine/AUTOMATED URINANALYSER)

Nitrite Negative Negative

(Urine/AUTOMATED URINANALYSER)

Bilirubin Negative Negative

(Urine/AUTOMATED URINANALYSER)

Protein Negative Negative

(Urine)



VERIFIED BY



VELURI

 PID No.
 : MED111034728
 Register On
 : 26/03/2022 10:15 AM

 SID No.
 : 422024590
 Collection On
 : 26/03/2022 12:03 PM

 Age / Sex
 : 49 Year(s) / Male
 Report On
 : 27/03/2022 4:19 PM

 Type
 : OP
 Printed On
 : 29/03/2022 4:33 PM

Ref. Dr : MediWheel

<u>Investigation</u>	<u>Observed</u> <u>Value</u>	<u>Unit</u>	<u>Biological</u> <u>Reference Interval</u>
Glucose (Urine)	+		Negative
Leukocytes (Urine)	Negative	leuco/uL	Negative
MICROSCOPY(URINE DEPOSITS)			
Pus Cells (Urine/Flow cytometry)	2-3	/hpf	3-5
Epithelial Cells (Urine)	1-2	/hpf	1-2
RBCs (Urine/Flow cytometry)	Nil	/hpf	NIL
Others (Urine)	Nil		Nil
Casts (Urine/Flow cytometry)	Nil	/hpf	0 - 1
Crystals (Urine)	Nil		NIL



VERIFIED BY



VELURI

 PID No.
 : MED111034728
 Register On
 : 26/03/2022 10:15 AM

 SID No.
 : 422024590
 Collection On
 : 26/03/2022 12:03 PM

 Age / Sex
 : 49 Year(s) / Male
 Report On
 : 27/03/2022 4:19 PM

 Type
 : OP
 Printed On
 : 29/03/2022 4:33 PM

Ref. Dr : MediWheel

InvestigationObservedUnitBiologicalValueReference Interval

IMMUNOHAEMATOLOGY

BLOOD GROUPING AND Rh TYPING 'B' 'Positive'

(EDTA Blood/Agglutination)



VERIFIED BY



VELURI

 PID No.
 : MED111034728
 Register On
 : 26/03/2022 10:15 AM

 SID No.
 : 422024590
 Collection On
 : 26/03/2022 12:03 PM

 Age / Sex
 : 49 Year(s) / Male
 Report On
 : 27/03/2022 4:19 PM

 Type
 : OP
 Printed On
 : 29/03/2022 4:33 PM

Ref. Dr : MediWheel

Investigation	<u>Observed</u> <u>Value</u>	<u>Unit</u>	<u>Biological</u> Reference Interval
BIOCHEMISTRY			
BUN / Creatinine Ratio	10		6 - 22
Glucose Fasting (FBS) (Plasma - F/GOD - POD)	107	mg/dL	Normal: < 100 Pre Diabetic: 100 - 125 Diabetic: >= 126

INTERPRETATION: Factors such as type, quantity and time of food intake, Physical activity, Psychological stress, and drugs can influence blood glucose level.

Glucose Fasting - Urine + Negative

(Urine - F)

Glucose Postprandial (PPBS) 233 mg/dL 70 - 140

(Plasma - PP/GOD - POD)

INTERPRETATION:

Factors such as type, quantity and time of food intake, Physical activity, Psychological stress, and drugs can influence blood glucose level. Fasting blood glucose level may be higher than Postprandial glucose, because of physiological surge in Postprandial Insulin secretion, Insulin resistance, Exercise or Stress, Dawn Phenomenon, Somogyi Phenomenon, Anti- diabetic medication during treatment for Diabetes.

Blood Urea Nitrogen (BUN)	9	mg/dL	7.0 - 21
(Serum/Urease-GLDH)			
Creatinine	0.9	mg/dL	0.9 - 1.3

(Serum/Jaffe Kinetic)

INTERPRETATION: Elevated Creatinine values are encountered in increased muscle mass, severe dehydration, Pre-eclampsia, increased ingestion of cooked meat, consuming Protein/ Creatine supplements, Diabetic Ketoacidosis, prolonged fasting, renal dysfunction and drugs such as cefoxitin ,cefazolin, ACE inhibitors ,angiotensin II receptor antagonists,N-acetylcyteine , chemotherapeutic agent such as flucytosine etc.

Uric Acid 5.0 mg/dL 3.5 - 7.2

(Serum/Uricase/Peroxidase)



VERIFIED BY



VELURI

 PID No.
 : MED111034728
 Register On
 : 26/03/2022 10:15 AM

 SID No.
 : 422024590
 Collection On
 : 26/03/2022 12:03 PM

 Age / Sex
 : 49 Year(s) / Male
 Report On
 : 27/03/2022 4:19 PM

 Type
 : OP
 Printed On
 : 29/03/2022 4:33 PM

Ref. Dr : MediWheel

 Investigation
 Observed Value
 Unit
 Biological Reference Interval

 IMMUNOASSAY

0.786

ng/mL

Prostate specific antigen - Total(PSA) (Serum/Chemiluminescent Microparticle Immunoassay(CMIA)) Normal: 0.0 - 4.0
Inflammatory & Non Malignant
conditions of Prostate & genitourinary
system: 4.01 - 10.0
Suspicious of Malignant disease of

Prostate: > 10.0

INTERPRETATION: Analytical sensitivity: 0.008 - 100 ng/mL

PSA is a tumor marker for screening of prostate cancer. Increased levels of PSA are associated with prostate cancer and benign conditions like bacterial infection, inflammation of prostate gland and benign hypertrophy of prostate/ benign prostatic hyperplasia (BPH).

Transient elevation of PSA levels are seen following digital rectal examination, rigorous physical activity like bicycle riding, ejaculation within 24 hours.

PSA levels tend to increase in all men as they age.

Clinical Utility of PSA:

ÉIn the early detection of Prostate cancer.

ÉAs an aid in discriminating between Prostate cancer and Benign Prostatic disease.

ÉTo detect cancer recurrence or disease progression.



-- End of Report --